Ascletis Pharma Net Income vs. Cash And Equivalents
| ASCLF Stock | USD 0.18 0.00 0.00% |
For Ascletis Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Ascletis Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Ascletis Pharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Ascletis Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Ascletis Pharma over time as well as its relative position and ranking within its peers.
Ascletis |
Ascletis Pharma Cash And Equivalents vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Ascletis Pharma's current stock value. Our valuation model uses many indicators to compare Ascletis Pharma value to that of its competitors to determine the firm's financial worth. Ascletis Pharma is number one stock in net income category among its peers. It also is number one stock in cash and equivalents category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Ascletis Pharma's earnings, one of the primary drivers of an investment's value.Ascletis Cash And Equivalents vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Ascletis Pharma |
| = | (199.02 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Ascletis Pharma |
| = | 2.5 B |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Ascletis Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Ascletis Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Ascletis Pharma will eventually generate negative long term returns. The profitability progress is the general direction of Ascletis Pharma's change in net profit over the period of time. It can combine multiple indicators of Ascletis Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer ASC61 and ASC63 for advanced solid tumors ASC60 to treat solid tumors and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the Peoples Republic of China. Ascletis Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 266 people.
Ascletis Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Ascletis Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Ascletis Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Ascletis Pharma's important profitability drivers and their relationship over time.
Use Ascletis Pharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ascletis Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ascletis Pharma will appreciate offsetting losses from the drop in the long position's value.Ascletis Pharma Pair Trading
Ascletis Pharma Pair Trading Analysis
The ability to find closely correlated positions to Ascletis Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ascletis Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ascletis Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ascletis Pharma to buy it.
The correlation of Ascletis Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ascletis Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ascletis Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ascletis Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Ascletis Pharma position
In addition to having Ascletis Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Equity ETFs Thematic Idea Now
Broad Equity ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Equity ETFs theme has 483 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Equity ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Ascletis Pink Sheet
To fully project Ascletis Pharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Ascletis Pharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Ascletis Pharma's income statement, its balance sheet, and the statement of cash flows.